Investing where IT and Biology intersect -
enabling Personalised Therapeutics
The Duplex Capital Team has strong sectoral experience & investing success since 2000.
Joey has focused his career on entrepreneurial healthcare and life science businesses in Europe and the USA. Most recently, he was head of the Life Science fund at M Ventures, a subsidiary of Merck KGaA, Darmstadt, Germany. Investing in research tools and enabling technologies worldwide, he served on the boards of Riffyn Inc, Indi Molecular Inc, DNA Script SA and Plexium Inc.
Joey began investing as venture capitalist with Delta Partners in 2004 after periods as an investment banker, a biotechnology executive and a digital health entrepreneur. He has a degree in medicine from Trinity College Dublin.
Ed has worked with growth companies his entire career. After exiting his first startup in the late 90s, he moved into venture capital, first with Amadeus Capital Partners and later with LMS Capital plc where he served on the investment committee.
Ed is Chairman of and a founding investor in ProColl, a synthetic biology spinout which closed its first institutional round in December 2020. He has a master’s degree in chemical engineering and an MBA from INSEAD, where he was a Sainsbury Management Fellow.
Ricardo has worked as an external auditor or consultant for a range of companies, has had experience as an entrepreneur and worked with Joey at M Ventures for three years.
He trained as a chemical engineer at ISEP and has developed PhD level work at Swansea University and The Methodist Research Institute in Texas medical center as a research fellow in the fields of nanotechnology, nanomedicine and microfluidics, particularly with platforms capable of performing single cell analyses and cell-to-cell interactions.